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The in-vitro activity of RP 59500, an injcctablc streptogramin derived from pristina-
mycin, was determined by agar dilution and compared with that of pristinamycin.
Two hundred and sixty-one recent clinical isolates of Gram-positive cocci were
tested against both antibiotics. The two compounds displayed similar activities. The
MIQgS of RP 59500 ranged from 0-5 to 2 mg/L in 114 strains of Staphylococcus
aureus showing various phenotypes of antibiotic resistance (penicillin-susceptible;
penicillin-resistant and methicillin-susceptible; methicillin-resistant; erythromycin-
resistant, either inducible or constitutive; quinolone-resistant). Similar results were
obtained with coagulase-negative staphylococci. RP 59500 was consistently active
against streptococci, with MIC^s of 0-25, 0-25 and 0-50 mg/L for Streptococcus
pyogenes (n = 20), Streptococcus agalactiae (n = 20) and Streptococcus pneumoniae
(n = 20), respectively. Enterococcus faecalis (n •= 20) appeared to be notably less
susceptible (MIQj, 8 mg/L). In view of this consistent activity against all staphylo-
cocci and streptococci tested, including multiply resistant isolates, RP 59500 merits
further investigation.
Introduction
There is an increasing incidence of severe infections caused by multi-resistant
Gram-positive bacteria, especially staphylococci. Such infections are difficult to treat,
even with newer antibiotics such as quinolones. Since pristinamycin (RP 7293) remains
a very potent anti-staphylococcal agent, its efficacy was compared with that of
RP 59500, a new injectable streptogramin antibiotic, against clinical isolates of
Gram-positive bacteria obtained from hospitalized patients. Most of these isolates were
associated with nosocomial infections, including strains of Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus pyogenes. Streptococcus pneumoniae.
Streptococcus agalactiae and Enterococcus faecalis, and many were multi-resistant.
Materials and methods
Antimicrobial powders of known potency were provided by Rhone-Poulenc Rorer,
Paris, and antibiotic solutions were prepared immediately before use. In total 244
clinical isolates were collected from patients admitted to three Swiss university
hospitals. In order to avoid duplicate strains, only one sample per patient was allowed,
and collection was maintained over a four-year period. A vancomycin-resistant strain
of Staphylococcus aureus (MIC, 8 mg/L) was obtained by passage on a vancomycin-
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containing agar gradient as described previously (Michea-Hamzehpour el al., 1987).
Strains were kept frozen in skimmed milk at — 70°C. Before study, samples were
thawed, streaked on to sheep blood agar and incubated overnight at 37°C.
MICS were determined by agar dilution according to the recommendations of the
National Committee for Clinical Laboratory Standards (1990). Mueller-Hinton agar
(Oxoid, Basingstoke) was used throughout these experiments. A multipoint-inoculator
(Cathra Systems, MTC Medical, Minnesota, USA) was used to inoculate plates with
lO'cfu/spot, in a volume of approximately 1 ph. All plates were incubated at 37°C for
18-20 h. The MIC was defined as the lowest concentration of an agent to completely
inhibit the growth of a given strain, disregarding a single colony or a faint haze caused
by the inoculum.
Results
The MICs of RP 59500 and RP 7293 for various Gram-positive cocci are shown in the
Table. The in-vitro activities of these two pristinamycin derivatives were similar; for
each strain the MICs were within one dilution of each other. These results indicate that
the injectable derivative, RP 59500, did not exert an antibacterial effect different from
that of the parent product, RP 7293. Anti-staphylococcal activity did not appear to
depend on either the species (S. aureus or S. epidermidis) or the resistance phenotype of
the strains. These pristinamycin derivatives were more active against streptococci
(S. pyogenes, S. agalactiae and S. pneumoniae), than against staphylococci, and no
resistant isolates were found among these species. However, E. faecalis appeared to be
markedly less susceptible than the other Gram-positive cocci studied.
Discussion
The most interesting finding of the present study was the fact that the in-vitro activities
of the pristinamycin derivatives studied remained almost unchanged, whatever the
resistance phenotype for other antibiotics. S. aureus exhibits a remarkable propensity
for resistance to various antibiotics, and this is accounted for by numerous resistance
mechanisms encoded by the chromosome, plasmids or transposons. Thus, in most parts
of the world, most staphylococci are resistant to penicillin and, depending on local
epidemiological conditions, a significant number of isolates are resistant to methicillin,
erythromycin, aminoglycosides and/or quinolones. More worrying is the fact that some
staphylococci are multi-resistant, thereby causing major therapeutic problems. A recent
example is the emergence of strains resistant to both methicillin and quinolones
(Schaefler, 1989).
In this context, the ability of pristinamycin derivatives to inhibit S. aureus strains
possessing various resistance phenotypes is potentially of clinical importance. The
persistent activity of RP 59500 and RP 7293 against strains expressing the MLSg
phenotype, and therefore resistant to macrolides, lincosamides and streptogramin B
(Ounissi & Courvalin, 1982; Duval, 1985), is particularly remarkable. MLSB resistance
results from a dimethylation of adenine in 23S ribosomal RNA that reduces the affinity
between the antibiotic and the ribosome. This alteration can be inducible, in which case
the resistance is apparently dissociated; in particular, the strain will be resistant to
erythromycin (inducer), but susceptible to spiramycin (non-inducer). In other cases,
MLSg resistance is constitutive, affecting all antibiotics of the group, including spira-
mycin. Pristinamycin derivatives contain both strcptogramins A and B, which act
Table. Antimicrobial activity of RP 59500 and RP 7293 against a variety of Gram-positive organisms
Bacterial species
(No. of isolates)
S. aureus (20)
5. aureus (20)
S. aureus (20)
S. aureus (20)
S. aureus (18)
S. aureus (16)
S. epidermidis (20)
S. epidermidis (20)
5. epidermidis (10)
S. pyogenes (20f
S. agalactiae (20)
E.faecalis (20)
S. pneumonia* (20)*
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R
S or R
S or R
R
S or R
R
S or R
S
S
R
S or R
Antibiotic phenotype
MET
S
S
®S or R
S or R
S or R
S
®S or R
S
S
R
S
ER
S
S
S or R
®
®S or R
S or R
S or R
S o r R
S or R
S
R
S
SPI
S
S
S
S
®S or R
S
S or R
S o r R
S
S
R
S
PEF
S
S
S
S
S
®S
s
®
s
sR
S
Antibiotic
RP 59500
MIC*
«JO-12
0-5
0-5
0-5
0-5
0-25
0-25
0-25
0-5
0-12
0-12
4-0
0-5
MIC*
0-5
0-5
0-2
10
10
0-5
0 25
10
10
0-12
0-12
8O
10
activity (mg/L)
R P '
MICJO
<0-12
025
10
0-5
0-5
0-25
0-12
0-25
0-25
<0O6
<0O6
20
O25
'293
M I Q ,
0-5
0-25
20
10
1O
10
0-5
10
0-5
<006
<0O6
4O
0-5
•Pen G, penicillin O; MET, Methicillin, ER, Erythromycin; SPI, Spiramycin; PEF., pefloxacin.
*S, Susceptible; R, resistant.
Including five erythromycin-resistant strains (MLS, inducible phenotype).
'Including three penicillin-resistant strains.
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syncrgically. It is interesting that resistance to streptogramin B, i.e. the MLSj pheno-
type, did not affect the activity of pristinamycins. This observation confirms the
findings of a previous study (Chabbert & Courvalin, 1971), in which synergy between
streptogramins A and B was shown to persist against staphylococci or streptococci
possessing the MLSB phenotype. However, our collection did not include bacteria
expressing the MLSB + SA or the LSA phenotype, which are known to be pristinamycin-
resistant (Buu-Hoi, 1985; Leclercq et al., 1985).
In addition to the activity of RP 59500 against both staphylococci and streptococci
having the MLSB phenotype, the lack of cross-resistance to this antibiotic in strains
resistant to /Mactams (including three penicillin-resistant pneumococci), quinolones or
aminoglycosides (27 strains tested, included in the Table, but not identified separately),
or vancomycin (a laboratory-generated mutant) deserves full consideration in the
perspective of future clinical studies.
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